142 related articles for article (PubMed ID: 1037483)
21. [Oral lisuride in Parkinson's disease].
Obeso JA; Luquin MR; MartÃnez Lage JM
Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
[No Abstract] [Full Text] [Related]
22. Bromocriptine and lisuride in Parkinson disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
[TBL] [Abstract][Full Text] [Related]
24. Letter: Growth-hormone response to bromocriptine in parkinsonism.
Shaw KM; Lees AJ; Hayes S; Ross EJ; Stern GM; Thompson BD
Lancet; 1976 Jan; 1(7952):194. PubMed ID: 54702
[No Abstract] [Full Text] [Related]
25. [Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].
Agnoli A; Casacchia M; Carolei A; Meco G; Zamponi A; Ruggieri S
Minerva Med; 1976 Nov; 67(53):. PubMed ID: 1036612
[TBL] [Abstract][Full Text] [Related]
26. Progress in the pharmacotherapy of Parkinsonism.
Calne DB; Eisler T; Gopinathan G; Williams A
Adv Biochem Psychopharmacol; 1980; 23():237-43. PubMed ID: 6104907
[No Abstract] [Full Text] [Related]
27. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
Baas H; Schneider E; Fischer PA; Japp G
J Neural Transm; 1985; 64(1):45-54. PubMed ID: 4067602
[TBL] [Abstract][Full Text] [Related]
28. Bromocriptine in Parkinson disease.
Lieberman AN; Goldstein M
Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
[TBL] [Abstract][Full Text] [Related]
29. Editorial: Bromocriptine.
Lancet; 1975 May; 1(7915):1076. PubMed ID: 48738
[No Abstract] [Full Text] [Related]
30. Pergolide versus bromocriptine.
Login IS
Neurology; 1984 Feb; 34(2):258. PubMed ID: 6538025
[No Abstract] [Full Text] [Related]
31. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
Jackson JA; Jankovic J; Ford J
Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139
[TBL] [Abstract][Full Text] [Related]
32. Parkinson's disease: a comparison of mesulergine and bromocriptine.
Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB
Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033
[TBL] [Abstract][Full Text] [Related]
33. Bromocriptine - an important advance.
Drug Ther Bull; 1976 Apr; 14(9):33-4. PubMed ID: 1278002
[No Abstract] [Full Text] [Related]
34. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
Haas JA; Lakke JP
Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
[No Abstract] [Full Text] [Related]
35. [Dopaminergic agonists in Parkinson disease].
Dubois B; Agid Y
Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
[No Abstract] [Full Text] [Related]
36. Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease.
Stern G; Lees A
Adv Neurol; 1987; 45():525-7. PubMed ID: 3103395
[No Abstract] [Full Text] [Related]
37. Bromocriptine:dopamine-receptor agonist.
Dipalma JR
Am Fam Physician; 1976 Dec; 14(6):88-9. PubMed ID: 1036662
[No Abstract] [Full Text] [Related]
38. Dopamine agonists as primary treatment in Parkinson's disease.
Rinne UK
Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
[No Abstract] [Full Text] [Related]
39. Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism.
Kartzinel R; Shoulson I; Calne DB
Neurology; 1976 Aug; 26(8):741-3. PubMed ID: 181692
[TBL] [Abstract][Full Text] [Related]
40. Bromocriptine--lisuride cross tolerance.
Giovannini P; Scigliano G; Grassi MP; Carella F; Parati E; Caraceni T
Ital J Neurol Sci; 1983 Apr; 4(1):129-30. PubMed ID: 6862842
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
